Caixin
Caixin Global – Latest China News & Headlines

Home >

TRENDING
A Billion People Are Now Part of China’s Credit Reporting System
Former Top Nanjing Political Adviser Commits Suicide
CNPC Plans $3.18 Billion Capital Increase in Finance Subsidiary
LATEST
Retired Shandong Securities Regulator Put Under Probe
China Raises the Bar for Futures Company Shareholders
CNPC Plans $3.18 Billion Capital Increase in Finance Subsidiary
Shanghai Regulators Push Didi to Expel Illegal Drivers After Accident
China Posts First Fiscal Revenue Decline in Six Months
A Billion People Are Now Part of China’s Credit Reporting System
Flow of Direct Investment Into China Continues to Grow Despite Trade Tensions
Trade Issues Could Trigger Competitive Devaluation: Ex-Central Bank Chief
Hong Kong Stock Exchange Chief Vows to Root Out Corrupt ‘Vermin’
China’s Property Investment Growth Slows
Shanghai Bets Big on Green Vehicle Future With ‘Hydrogen Energy Port’
Beijing Says Recent Drop in Rare-Earth Exports Caused by Market, Not Tightened Rules
China Proposes Tighter Rules on Foreign Companies Transferring Data Out of Country
Exclusive: Baoshang Takeover Impact Diminishing, Top Regulator Says
Former Top Nanjing Political Adviser Commits Suicide
Warburg-Backed ESR Shelves $1.25 Billion Hong Kong IPO
BMW's Production Shift to China Pays Off With Jump in X3 Sales
China Will Deliver Its Own Entity List Soon, Ministry Says
China Reduces High-Risk Financial Assets by Net $2 Trillion: Regulator
Central Bank Chief Calls on Shanghai to Step Up Services for Global Investors

Fran Wang / Feb 06, 2019 06:47 PM / Business & Tech

Photo: VCG

Photo: VCG

EdiGene Inc., a Beijing-based company developing genome-editing technologies into therapeutics for genetic diseases and cancer, announced it has completed a new round of fund-raising worth $10 million.

The company’s series pre-B plus financing was led by venture capital firm Green Pine Capital Partners, which invests in biotech, new materials, new resources, artificial intelligence and other areas, EdiGene said in a statement earlier this week.

“Our portfolio is entering into an exciting stage, and this new round of financing further validates and continues to support our strategy of translating proprietary platforms into potential therapeutics to patients in need,” said EdiGene CEO Wei Dong.

IDG Capital and Lilly Asia Ventures, which led investment in EdiGene’s series A and series B financing, respectively, are among other investors in this round, according to the statement.

EdiGene was founded in 2015 and currently has subsidiaries in southern China’s Guangzhou and Cambridge in the U.S.

Genome editing has been in the spotlight since late last year, when Chinese scientist He Jiankui said a team he led had removed genes from two fetuses in an attempt to make them HIV-resistant. He said the resulting children were born in November. This led to international condemnation, with the government ordering inspections of gene-editing work at universities nationwide and He himself disappearing from public view.

Related: ‘Pursuit of Fame’ Drove Controversial Gene-Editing Project, Investigation Says

Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.